Fexofenadine hydrochloride in the treatment of allergic disease: A review

Journal of Asthma and Allergy

Volumn , Issue 1, 2008, Pages 19-29

  Axelrod, David ^a,b   Bielory, Leonard ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Department of Medicine ^*  (United States)

^c INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

Allergy; Fexofenadine; Formulations; Oral suspension; Pharmacology

Indexed keywords

CXCL11 CHEMOKINE; CYCLOOXYGENASE 2; CYTOCHROME P450 3A4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROMYCIN; FEXOFENADINE; GELATINASE A; GELATINASE B; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; OMEPRAZOLE; PLACEBO; PROBENECID; PROSTAGLANDIN F2 ALPHA; RAMATROBAN; RANTES; RIFAMPICIN; RIFAMYCIN; RITONAVIR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRYPTASE; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERAPAMIL;

ALLERGIC DISEASE; ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ASTHMA; ATOPIC DERMATITIS; BIOEQUIVALENCE; CHEMOTAXIS; CHEST TIGHTNESS; CHRONIC IDIOPATHIC URTICARIA; CHRONIC URTICARIA; CLINICAL TRIAL; COUGHING; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EOSINOPHIL; FEVER; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; FRUIT JUICE; GRAPEFRUIT JUICE; HAY FEVER; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; INCREASED APPETITE; INFECTION; INFLAMMATION; NONHUMAN; NOSE CONGESTION; OPSONIZATION; ORANGE JUICE; OTITIS MEDIA; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRURITUS; QT PROLONGATION; RASH; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

EID: 77953422183     PISSN: None     EISSN: 11786965     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Abdelaziz MM, Devalia JL, Khair OA, et al. 1998. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol, 101:410-420
2. Adenot M, Lahana R, Adenot M, et al. 2004. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates. J Chem Inf Comput Sci, 44:239-248
3. Akiyama S, Cornwell MM, Kuwano M, et al. 1988. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol, 33:144-147
4. Allocco FT, Votypka V, deTineo M, et al. 2002. Effects of fexofenadine on the early response to nasal allergen challenge. Ann Allergy Asthma Immunol, 89:578-584
5. Asano K, Kanai K, Furuta A, et al. 2007. Suppressive activity of fexofenadine hydrochloride on nitric oxide production in-vitro and in-vivo. J Pharm Pharmacol, 59:1389-1395
6. Asano K, Kanai K, Suzaki H, et al. 2004a. Suppressive activity of fexofenadine hydrochloride on the production of eosinophil chemoattractants from human nasal fibroblasts in vitro. Arzneimittelforschung, 54:436-443 (Pubitemid 39119240)
7. Asano K, Kanai K, Suzaki H, et al. 2004b. Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro. Int Arch Allergy Immunol, 133:267-275
8. Asano K, Kanai KI, Suzaki H, et al. 2004c. Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro. Clin Exp Allergy, 34:1890-1898.
9. Baltes S, Gastens AM, Fedrowitz M, et al. 2007. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology, 52:333-346
10. Banerji A, Long AA, Camargo CA Jr. 2007. Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. Allergy Asthma Proc, 28:418-426
11. Banfield C, Gupta S, Marino M, et al. 2002. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet, 41:311-318
12. Bielory L. Leonov A. 2008. Stereoconfiguration of antiallergic and immunologic drugs. Ann Allerg Asthma Immunol, 100:1-8.
13. Bower EA, Moore JL, Moss M, et al. 2003. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med, 74:145-152
14. Brannan JD, Anderson SD, Gomes K, et al. 2001. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med, 163:1420-1425
15. Bronsky EA, Falliers CJ, Kaiser HB, et al. 1998. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc, 19:135-141
16. Casale TB, Andrade C, Qu R, et al. 1999. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc, 20:193-198
17. Cassano N, Filotico R, D'Argento V, et al. 2002. In vivo anti-inflammatory effects of fexofenadine in chronic idiopathic urticaria. J Eur Acad Dermatol Venereol, 16:421-422
18. Charuk JH, Loo TW, Clarke DM, et al. 1994. Interaction of rat kidney P-glycoprotein with a urinary component and various drugs including cyclosporin A. Am J Physiol, 266:F66-75.
19. Chiou WL, Chung SM, Wu TC. 2000. Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res, 17:903-905
20. Choi SU, Park SH, Kim KH, et al. 1998. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs, 9:255-261
21. Ciprandi G, Cirillo I, Vizzaccaro A, et al. 2004. Mizolastine and fexofenadine modulate cytokine pattern after nasal allergen challenge. Allerg Immunol (Paris), 36:146-150
22. Craig-McFeely PM, Acharya NV, Shakir SA, et al. 2001. Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997. Eur J Clin Pharmacol, 57:313-320
23. Craig-McFeely PM, Freemantle SL, Pearce GL, et al. 2000. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Br J Gen Pract, 50:148.
24. Crowe A, Ilett KF, Karunajeewa HA, et al. 2006a. Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob Agents Chemother, 50:3504-3506
25. Crowe A, Teoh YK, Crowe A, et al. 2006b. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J Drug Target, 14:291-300.
26. Cvetkovic M, Leake B, Fromm MF, et al. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos, 27:866-871
27. Dhar S, Hazra PK, Malakar S, et al. 2000. Fexofenadine-induced QT prolongation: a myth or fact? Br J Dermatol, 142:1260-1261
28. Dicpinigaitis PV, Gayle YE, Dicpinigaitis PV, et al. 2003. Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function. Br J Clin Pharmacol, 56:501-504
29. DiDiodato G, Sharom FJ. 1997. Interaction of combinations of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporter. Biochem Pharmacol, 53:1789-1797
30. Doran A, Obach RS, Smith BJ, et al. 2005. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos, 33:165-174
31. Drescher S, Schaeffeler E, Hitzl M, et al. 2002. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol, 53:526-534
32. Dresser GK, Bailey DG, Leake BF, et al. 2002. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther, 71:11-20.
33. Dresser GK, Kim RB, Bailey DG, et al. 2005. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther, 77:170-177
34. Ejsing TB, Morling N, Linnet K, et al. 2007. A review on the relation between the brain-serum concentration ratio of drugs and the influence of P-glycoprotein. Drug Metabol Drug Interact, 22:113-129
35. Elsinga PH, Hendrikse NH, Bart J, et al. 2004. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des, 10:1493-1503
36. Faassen F, Vogel G, Spanings H, et al. 2003. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm, 263:113-122
37. Fardon TC, Lee DK, Hodge MR, et al. 2005. Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. Ann Allergy Asthma Immunol, 95:259-265
38. Feng B, Mills JB, Davidson RE, et al. 2008. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos, 36:268-275
39. Fokkens WJ, Broekhuis-Fluitsma DM, Rijntjes E, et al. 1991. Langerhans cells in nasal mucosa of patients with grass pollen allergy. Immunobiology, 182:135-142
40. Fromm MF. 2000. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther, 38:69-74.
41. Garrigues A, Nugier J, Orlowski S, et al. 2002. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem, 305:106-114
42. Gelfand EW, Cui ZH, Takeda K, et al. 2002. Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol, 110:85-95.
43. Giraud T, Giraud T. 1999. QT lengthening and arrhythmias associated with fexofenadine.[comment]. Lancet, 353:2072-2073
44. Gouaze V, Liu YY, Prickett CS, et al. 2005. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res, 65:3861-3867
45. Graft DF, Bernstein DI, Goldsobel A, et al. 2001. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol, 87:22-26
46. Grewal IS, Flavell RA. 1996. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today, 17:410-414
47. Grubbe RE Nayak A, Kittner B, et al. 2007. The pharmacokinetics (PK), safety and tolerability of fexofenadine HCL 6 mg/mL suspension in children with allergic rhinitis (AR): a multicenter, open-label, single-dose study. J Allergy Clin Immunol, 119:S143.
48. Hamman MA, Bruce MA, Haehner-Daniels BD, et al. 2001. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther, 69:114-121
49. Hampel FC, Kittner B, van Bavel JH, et al. 2007. Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. Ann Allergy Asthma Immunol, 99:549-554 (Pubitemid 350308755)
50. Handa S, Dogra S, Kumar B, et al. 2004. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. [see comment]. J Dermatolog Treat, 15:55-57
51. Hanko E, Tommarello S, Watchko JF, et al. 2003. Administration of drugs known to inhibit P-glycoprotein increases brain bilirubin and alters the regional distribution of bilirubin in rat brain.[see comment]. Pediatr Res, 54:441-445
52. Hayeshi R, Masimirembwa C, Mukanganyama S, et al. 2006. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci 29:70-81.
53. Hindmarch I, Shamsi Z, Kimber S, et al. 2002. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy, 32:133-139
54. Hindmarch I, Shamsi Z, Stanley N, et al. 1999. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol, 48:200-206
55. Hirano H. 1989. [Studies on the degranulation and histamine release of purified rat peritoneal mast cells. The inhibitory effect of histamine and other chemicals]. Nippon Ika Daigaku Zasshi, 56:392-399
56. Ibrahim S, Peggins J, Knapton A, et al. 2000. Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther, 295:1276-1283
57. Ishizaka T, Ishizaka K. 1977. Immunological events at the surface of basophil granulocytes and mast cells which induce degranulation. Scand J Respir Dis Suppl, 98:13-22.
58. Ito T, Yano I, Tanaka K, et al. 1997. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther, 282:955-960
59. Jette L, Murphy GF, Leclerc JM, et al. 1995. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol, 50:1701-1709
60. Johnson WW. 2002. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods Find Exp Clin Pharmacol, 24:501-514
61. Juergens UR, Darlath W, Stober M, et al. 2006a. Differential effects of fexofenadine on arachidonic acid metabolism in cultured human monocytes. Pharmacology, 76:40-45
62. Juergens UR, Gillissen A, Uen S, et al. 2006b. New evidence of H1-receptor independent COX-2 inhibition by fexofenadine HCl in vitro. Pharmacology, 78:129-135
63. Kamath AV, Yao M, Zhang Y, et al. 2005. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci, 94:233-239
64. Kamei H, Noda Y, Ishikawa K, et al. 2003. Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers. Hum Psychopharmacol, 18:611-618
65. Kawashima M, Harada S, Tango T, et al. 2002. Review of fexofenadine in the treatment of chronic idiopathic urticaria. Int J Dermatol, 41:701-706
66. Kawashima M, Tango T, Noguchi T, et al. 2003. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol, 148:1212-1221
67. Ketabi-Kiyanvash N, Weiss J, Haefeli WE, et al. 2003. P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine. Addict Biol, 8:413-418
68. Kharasch ED, Walker A, Hoffer C, et al. 2005. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J Clin Pharmacol, 45:79-88.
69. Kim RB, Kim RB. 2002. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev, 34:47-54.
70. King M, Su W, Chang A, Zuckerman A, et al. 2001. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs.[see comment]. Nat Neurosci, 4:268-274
71. Kulthanan K, Gritiyarangsan P, Sitakalin C, et al. 2001. Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria. J Med Assoc Thai, 84:153-159
72. Lee CH, Lee CH. 2002. Differential regulation of P-glycoprotein genes in primary rat hepatocytes by collagen sandwich and drugs. J Cell Biochem, 86:12-20.
73. Leung DY. 1998. Molecular basis of allergic diseases. Mol Genet Metab, 63:157-167
74. Leung S, Bendayan R. 1999. Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs. Can J Physiol Pharmacol, 77:625-630
75. Ling V. 1992. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer, 69:2603-2609
76. Litman T, Skovsgaard T, Stein WD, et al. 2003. Pumping of drugs by P-glycoprotein: a two-step process? J Pharmacol Exp Ther, 307:846-853
77. Loo TW, Bartlett MC, Clarke DM, et al. 2003. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem, 278:39706-39710
78. Makowski P, Pikula S. 1997. Participation of the multispecific organic anion transporter in hepatobiliary excretion of glutathione S-conjugates, drugs and other xenobiotics. Pol J Pharmacol, 49:387-394
79. Mansfield L, Mendoza C, Flores J, et al. 2003. Effects of fexofenadine, diphenhydramine, and placebo on performance of the test of variables of attention (TOVA). [erratum Ann Allergy Asthma Immunol, 2003; 91(2):167]. Ann Allergy Asthma Immunol, 90:554-559
80. Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. 2004. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis - a pooled analysis of three studies. Pediatr Allergy Immunol, 15:253-260
81. Milgrom H, Kittner B, Lanier R, et al. 2007. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol, 99:358-363
82. Milne RW, Larsen LA, Jorgensen KL, et al. 2000. Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm Res, 17:1511-1515
83. Miura M, Uno T, Tateishi T, et al. 2007. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality, 19:223-227
84. Miyabe S, Koizuka I, Ochi K, et al. 2003. Effect of fexofenadine hydrochloride on cedar pollinosis. Auris Nasus Larynx, 30(Suppl):S61-8.
85. Mollgard L, Hellberg E, Smolowicz A, et al. 2001. Interactions between P-glycoprotein and drugs used in the supportive care of acute myeloid leukemia patients. Leuk Lymphoma, 42:177-185
86. Morrison D, Sahasranaman S. 2007. The 30 mg dose of fexofenadine HCL 6 mg/mL suspension is bioequivalent to the marketed 30 mg tablet in healthy adult subjects under fasted conditions: a randomized crossover, open-label study. J Allergy Clin Immunol, 119:S143.
87. Nelson HS, Reynolds R, Mason J, et al. 2000. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol, 84:517-522
88. Neuhoff S, Langguth P, Dressler C, et al. 2000. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther, 38:168-179
89. Ngamphaiboon J, Direkwattanachai C, Visitsunthorn N, et al. 2005. The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis. Asian Pac J Allergy Immunol, 23:169-174
90. Nicholson AN, Stone BM, Turner C, et al. 2000. Antihistamines and aircrew: usefulness of fexofenadine. Aviat Space Environ Med, 71:2-6.
91. Okubo K, Gotoh M, Shimada K, et al. 2005. Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol, 136:148-154
92. Orlowski S, Garrigos M. 1999. Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. Anticancer Res, 19:3109-3123
93. Pascaud C, Garrigos M, Orlowski S. 1998. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J, 333:351-358
94. Petri N, Tannergren C, Rungstad D, et al. 2004. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res, 21:1398-1404
95. Pinto YM, van Gelder IC, Heeringa M, et al. 1999. QT lengthening and life-threatening arrhythmias associated with fexofenadine. [see comment]. Lancet, 353:980. (Pubitemid 29132610)
96. Potter PC, Schepers JM, Van Niekerk CH, et al. 2003. The effects of fexofenadine on reaction time, decision-making, and driver behavior. Ann Allergy Asthma Immunol, 91:177-181
97. Pratt C, Brown AM, Rampe D, et al. 1999. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy, 29(Suppl 3):212-216
98. Rebbeor JF, Senior AE. 1998. Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted form. Biochim Biophys Acta, 1369:85-93.
99. Ridout F, Hindmarch I, Ridout F, et al. 2003a. The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. Ann Allergy Asthma Immunol, 90:404-410 (Pubitemid 36459045)
100. Ridout F, Shamsi Z, Meadows R, et al. 2003b. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther, 25:1518-1538
101. Robbins DK, Castles MA, Pack DJ, et al. 1998. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos, 19:455-463
102. Russell T, Stoltz M, Weir S, et al. 1998. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther, 64:612-621 (Pubitemid 29011381)
103. Safa AR, Safa AR. 2004. Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anti-Canc Agents, 4:1-17.
104. Sakairi T, Suzuki K, Makita S, et al. 2005. Effects of fexofenadine hydrochloride in a guinea pig model of antigen-induced rhinitis. Pharmacology, 75:76-86.
105. Saraswat A, Saraswat M, Saraswat A, et al. 2006. Pustular exacerbation of psoriasis due to fexofenadine. Clin Exp Dermatol, 31:477-478
106. Savolainen J, Edwards JE, Morgan ME, et al. 2002. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab Dispos, 30:479-482
107. Schinkel AH, Wagenaar E, Mol CA, et al. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest, 97:2517-2524
108. Sharom FJ. 1997. The P-glycoprotein efflux pump: how does it transport drugs?[see comment]. J Membr Biol, 160:161-175
109. Shimizu M, Fuse K, Okudaira K, et al. 2005. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos, 33:1477-1481
110. Shirasaka Y, Onishi Y, Sakurai A, et al. 2006. Evaluation of human P-glycoprotein (MDR1/ABCB1) ATPase activity assay method by comparing with in vitro transport measurements: Michaelis-Menten kinetic analysis to estimate the affinity of P-glycoprotein to drugs. Biol Pharm Bull, 29:2465-2471
111. Shon JH, Yoon YR, Hong WS, et al. 2005. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther, 78:191-201.
112. Shukla S, Sauna ZE, Ambudkar SV. 2008. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrugresistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.[comment]. Leukemia, 22:445-447
113. Simons FE, Bergman JN, Watson WT, et al. 1996. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol, 98:1062-1064
114. Simons F, Estelle R, Semus M, et al. 2003. H1-antihistaminic activity of cetirizine and fexofenadine in allergic children. Pediatr Allergy Immunol, 14:207-211 (Pubitemid 36713380)
115. Smit JW, Duin E, Steen H, et al. 1998. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br J Pharmacol, 123:361-370
116. Stoltz M, Arumugham T, Lippert C, et al. 1997. Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A). Biopharm Drug Dispos, 18:645-648
117. Stone BM, Turner C, Mills SL, et al. 1999. Studies into the possible central effects of the H-1 receptor antagonist, fexofenadine. Int Arch Allergy Immunol, 118:338.
118. Storch CH, Theile D, Lindenmaier H, et al. 2007. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol, 73:1573-1581
119. Tahara H, Kusuhara H, Fuse E, et al. 2005. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. [erratum Drug Metab Dispos, 200634(6):1079]. Drug Metab Dispos, 33:963-968
120. Tahara H, Kusuhara H, Maeda K, et al. 2006. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos, 34:743-747
121. Takahata T, Yasui-Furukori N, Yoshiya G, et al. 2004. Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates. Basic Clin Pharmacol Toxicol, 94:252-256
122. Tannergren C, Knutson T, Knutson L, et al. 2003. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br J Clin Pharmacol, 55:182-190
123. Tashiro M, Horikawa E, Mochizuki H, et al. 2005. Effects of fexofenadine and hydroxyzine on brake reaction time during car-driving with cellular phone use. Hum Psychopharmacol, 20:501-509
124. Terao T, Hisanaga E, Sai Y, et al. 1996. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol, 48:1083-1089
125. Theunissen EL, Jonkman LM, Kuypers KP, et al. 2006a. A combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performance. J Psychopharmacol, 20:496-505.
126. Theunissen EL, van Kroonenburgh MJ, van Deursen JA, et al. 2006b. Stimulating effects of the antihistamine fexofenadine: testing the dopamine transporter hypothesis. Psychopharmacology (Berl ), 187:95-102.
127. Uno T, Shimizu M, Sugawara K, et al. 2006. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos, 34:1875-1879
128. van Heeswijk RP, Bourbeau M, Campbell P, et al. 2006. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol, 46:758-767
129. Vercelli D, Jabara HH, Arai K, et al. 1989. Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. J Exp Med, 169:1295-1307
130. Wang JS, Zhu HJ, Markowitz JS, et al. 2006. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl), 187:415-423
131. Wang Z, Hamman MA, Huang SM, et al. 2002. Effect of St John's wort on the pharmacokinetics of fexofenadine. [see comment]. Clin Pharmacol Ther, 71:414-420
132. Watanabe N, Matsuda E, Masuda A, et al. 2004. The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralis. Int Immunopharmacol, 4:367-375
133. Weiler JM, Bloomfield JR, Woodworth GG, et al. 2000. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. [see comment]. Ann Intern Med, 132:354-363
134. Weiss J, Kerpen CJ, Lindenmaier H, et al. 2003. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther, 307:262-267
135. Yi SY, Hong KS, Lim HS, et al. 2004. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther, 76:418-427